Sifat Sharmin

Comparative effectiveness in multiple sclerosis: A methodological comparison

Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola, et al.

Journal article  |  2023  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trial..

Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis

Yew Li Dang, Vivien TY Yong, Sifat Sharmin, Piero Perucca, Tomas Kalincik

Journal article  |  2023  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Multiple sclerosis patients experience 3-6 times more seizures than the general population, but observations vary amon..

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

N Seery, S Sharmin, V Li, A Nguyen, C Meaton, R Atvars, N Taylor, K Tunnell, J Carey, MP Marriott, KA Buzzard, I Roos, C Dwyer, J Baker, L Taylor, K Spriggs, TJ Kilpatrick, T Kalincik, M Monif

Conference Proceedings  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S Sharmin, C Malpas, J Lechner-Scott, M Slee, P McCombe, S Vucic, E Butler, S Hodgkinson, M Barnett, O Skibina, A van der Walt, K Buzzard, C Shaw, A Kermode, B Taylor, N Shuey, R Macdonell, H Butzkueven, T Kalincik

Journal article  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); how..

External validation of a clinical prediction model in multiple sclerosis

Nahid Moradi, Sifat Sharmin, Charles B Malpas, Vahid Shaygannejad, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J Khoury, Recai Turkoglu, Rana Karabudak, Nevin Shalaby, Aysun Soysal, Ayse Altintas, Jihad Inshasi, Talal Al-Harbi, Raed Alroughani, Tomas Kalincik, Study Grp MSBase

Journal article  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Timely initiation of disease modifying therapy is crucial for managing multiple sclerosis (MS). OBJECTIVE: We aimed to..

Updated Results of the COVID-19 in MS Global Data Sharing Initiative Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Steve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, Edward De Brouwer, Lotte Geys, Tina Parciak, Anne Helme, Nick Rijke, Jan A Hillert, Yves Moreau, Gilles Edan, Sifat Sharmin, Tim Spelman, Robert McBurney, Hollie Schmidt, Arnfin B Bergmann, Stefan Braune, Alexander Stahmann, Rod M Middleton, Amber Salter, et al.

Journal article  |  2022  |  NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION

BACKGROUND AND OBJECTIVES: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies..

Comparative effectiveness of autologous haematopoietic stem cell transplantation with immune reconstitution therapies in relapsing-remitting MS

T Kalincik, S Sharmin, I Roos, MS Freedman, H Atkins, J Burman, J Massey, I Sutton, B Withers, R Macdonell, A Grigg, O Torkildsen, L Bo, AK Lehmann, D Horakova, EK Havrdova, E Krasulova, M Trneny, T Kozak, A van der Walt, et al.

Conference Proceedings  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

Effectiveness of autologous haematopoietic stem cell transplantation in comparison with natalizumab in progressive MS

T Kalincik, S Sharmin, I Roos, J Massey, I Sutton, B Withers, M Freedman, H Atkins, D Horakova, E Kubala Havrdova, E Krasulova, M Trneny, T Kozak, J Burman, R Macdonell, A Grigg, O Torkildsen, L Bo, AK Lehmann, B Sharrack, et al.

Conference Proceedings  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

S Sharmin, I Roos, S Simpson-Yap, C Malpas, M Martinez Sanchez, S Ozakbas, D Horakova, EK Havrdova, F Patti, R Alroughani, V Shaygannejad, G Izquierdo, S Eichau, C Boz, M Zakaria, M Onofrj, A Lugaresi, B Weinstock-Guttman, A Prat, M Girard, et al.

Conference Proceedings  |  2022  |  MULTIPLE SCLEROSIS JOURNAL

Efficacy of botulinum toxin type a in the targeted treatment of sleep bruxism: a double-blind, randomised, placebo-controlled, cross-over study

Belinda Cruse, Thanuja Dharmadasa, Elise White, Callum Hollis, Andrew Evans, Sifat Sharmin, Tomas Kalincik, Lynette Kiers

Journal article  |  2022  |  BMJ NEUROLOGY OPEN

BACKGROUND: Intramuscular injections of botulinum toxin A (BTX-A) have been used in the treatment of sleep bruxism (SB) however co..